Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Jun 2022
Drug importation is dangerous and won’t lower prices
9 June 2022 - Federal and state governments continually insert themselves into the medical marketplace in an attempt to lower prescription ...
Posted by Michael Wonder on 09 Jun 2022
PHARMAC joins ACT’s call for a medicines strategy
8 June 2022 - “It appears that everyone wants a dedicated Medicines Strategy apart from Andrew Little, who is too ...
Posted by Michael Wonder on 09 Jun 2022
Lupin receives tentative approval from U.S. FDA for ivacaftor tablets
8 June 2022 - Lupin today announced that it has received tentative approval from the United States FDA for its ...
Posted by Michael Wonder on 09 Jun 2022
U.S. FDA approves Foundation Medicine’s FoundationOne CDx as a companion diagnostic for Roche’s Rozlytrek (entrectinib)
9 June 2022 - This approval marks the first and only companion diagnostic indication for Rozlytrek, and another important milestone in ...
Posted by Michael Wonder on 09 Jun 2022
AlgoTx’s ATX01 granted fast track designation by FDA for chemotherapy-induced neuropathic pain
9 June 2022 - AlgoTx announced today that it has received fast track designation from the U.S. FDA for the ...
Posted by Michael Wonder on 09 Jun 2022
COVID-19 vaccine weekly safety report (9 June 2022)
9 June 2022 - To 5 June 2022, the TGA has received 577 reports which have been assessed as likely to ...
Posted by Michael Wonder on 09 Jun 2022
The days of the independent republic of PHARMAC are far from over
9 June 2022 - When he announced the government’s response to the recent independent review of PHARMAC Health Minister Andrew Little ...
Posted by Michael Wonder on 09 Jun 2022
Scynexis announces submission of supplemental new drug application of Brexafemme (ibrexafungerp tablets) to the U.S. FDA for an expanded indication for the prevention of recurrent vaginal yeast infection
8 June 2022 - Regulatory submission for the label extension is supported by positive data from the pivotal Phase 3 ...
Posted by Michael Wonder on 09 Jun 2022
Bydureon BCise (exenatide prolonged-release) approved in the EU for paediatric patients with type 2 diabetes
8 June 2022 - First once weekly GLP-1 treatment option for paediatric patients with type-2 diabetes in the EU. ...
Posted by Michael Wonder on 08 Jun 2022
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
8 June 2022 - Approval is based on the phase I/II GO29781 study, where Lunsumio induced high complete response rates, with ...
Posted by Michael Wonder on 08 Jun 2022
Health Canada approves Tabrecta: targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
8 June 2022 - Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for ...
Posted by Michael Wonder on 08 Jun 2022
EMA adopts first list of critical medicines for COVID-19
8 June 2022 - On 7 June 2022, the EMA’s Medicines Shortages Steering Group adopted the list of critical medicines for ...
Posted by Michael Wonder on 08 Jun 2022
TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
Posted by Michael Wonder on 08 Jun 2022
Irish parents ‘breaking down and crying’ as children denied life changing cystic fibrosis medication
8 June 2022 - Sarah O’Keeffe found out that her son would not be getting the medication that would improve his ...
Posted by Michael Wonder on 08 Jun 2022
Allogene Therapeutics announces the FDA granted regenerative medicine advanced therapy designation to ALLO-501A for large B-cell Lymphoma
8 June 2022 - In the ALPHA trials with ALLO-501 and ALLO-501A, treatment was initiated approximately 2 days from enrollment, eliminating ...